FLORENCE, Italy and NEW YORK, Aug. 19, 2022 /PRNewswire/ — The Menarini Group ('Menarini'), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ('Stemline'), a wholly-owned subsidiary of the Menarini Group, today announced that EMA has validated the Marketing Authorization Application (MAA) for elacestrant, a selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer. Validation of the application confirms the submission is complete and begins EMA's centralized review procedure.

http://www.padovanews.it/2022/08/20/menarini-groups-elacestrant-marketing-authorization-application-accepted-for-review-by-the-european-medicines-agency-ema-for-the-treatment-of-er-her2-advanced-or-metastatic-breast-cancer/

#padovanews